Expert Interview
Discussing the Phase 3 study of Aquestive Therapeutics' Anaphylm (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions
Ticker(s): AQSTInstitution: University of Tennessee
- Associate Professor and Director of Allergy & Immunology training at the University of Tennessee.
- Manages 3 patients with Hereditary angioedema.
- Research focuses on food allergy, anaphylaxis, primary immune deficiency, and drug allergy.
How many patients do you manage for Anaphylactic Shock?
Added By: ben_adminWhat are your thoughts on the potential of AQST-109?
Added By: ben_adminHow does AQST-109 compare to the Epipen and other epinephrine medications?
Added By: ben_adminWill patients prefer a needle-free, orally administered epinephrine medication?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
